These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18220056)
1. A poke in the eye. Gurney M Nurs Older People; 2007 Dec; 19(10):3. PubMed ID: 18220056 [No Abstract] [Full Text] [Related]
2. AMD: out of sight out of mind. Pountney D Nurs Older People; 2007 Dec; 19(10):16-9. PubMed ID: 18220063 [No Abstract] [Full Text] [Related]
3. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery. Harris MJ BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986 [No Abstract] [Full Text] [Related]
4. Bevacizumab in ophthalmology: the controversy moves forward. Gillies MC Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588 [No Abstract] [Full Text] [Related]
5. Off-label prescribing in macular degeneration. McCartney M BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651 [No Abstract] [Full Text] [Related]
6. Cost comparison of ranibizumab and bevacizumab. Jackson TL; Kirkpatrick L BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536 [No Abstract] [Full Text] [Related]
7. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)]. Holz FG MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376 [No Abstract] [Full Text] [Related]
8. Study aims to clarify efficacy, safety of eye drug treatments. Mitka M JAMA; 2007 Apr; 297(14):1538-9. PubMed ID: 17426265 [No Abstract] [Full Text] [Related]
9. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? Lotery A; MacEwen C BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142 [No Abstract] [Full Text] [Related]
11. [Vision for patients with macular degeneration]. Paukstadt W MMW Fortschr Med; 2007 Jan; 149(3):10-2. PubMed ID: 17619375 [No Abstract] [Full Text] [Related]
12. Why using Avastin for eye disease is so difficult. Torjesen I BMJ; 2012 May; 344():e3012. PubMed ID: 22549057 [No Abstract] [Full Text] [Related]
13. Cancer drug offers effective, cheaper option for AMD. Stephenson J JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231 [No Abstract] [Full Text] [Related]
14. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Harvey KJ; Day RO; Campbell WG; Lipworth W Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867 [TBL] [Abstract][Full Text] [Related]
15. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows. Hawkes N BMJ; 2012 May; 344():e3275. PubMed ID: 22573655 [No Abstract] [Full Text] [Related]
16. Bevacizumab versus ranibizumab: why are we not playing the joker? Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322 [No Abstract] [Full Text] [Related]
17. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay. Silver J JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863 [No Abstract] [Full Text] [Related]
18. The use of bevacizumab for the treatment of colorectal cancer. Beaumont I Int J Palliat Nurs; 2010 Dec; 16(12):576. PubMed ID: 21240099 [No Abstract] [Full Text] [Related]
19. What is the real cost of bevacizumab for patients with advanced bowel cancer? Dixon L Int J Palliat Nurs; 2010 Dec; 16(12):577. PubMed ID: 21240100 [No Abstract] [Full Text] [Related]
20. An ethical view of the ranibizumab and bevacizumab controversy. Packer S; Jampol LM Arch Ophthalmol; 2008 Feb; 126(2):286; author reply 286-7. PubMed ID: 18268234 [No Abstract] [Full Text] [Related] [Next] [New Search]